Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...152153154155156157158159160161162...859860»
  • ||||||||||  CCX832 / GSK, Amgen
    Journal:  Chemerin is resident to vascular tunicas and contributes to vascular tone. (Pubmed Central) -  Jun 28, 2023   
    Inhibition of the receptor Chemerin1 by the receptor antagonist CCX832 resulted in the loss of vascular tone that supports potential contributions of chemerin by both perivascular adipose tissue and the media...These data suggest that vessel-derived chemerin may support vascular tone locally through constitutive activation of Chemerin1. This posits chemerin as a potential therapeutic target in blood pressure regulation.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Microneedle Patch Delivery of PROTACs for Anti-Cancer Therapy. (Pubmed Central) -  Jun 28, 2023   
    Co-administration of ERD308 and Palbociclib exhibits excellent efficacy by over 80% tumor reduction as well as a good safety profile. Our work demonstrates the feasibility and proof-of-concept therapeutic potential of using microneedle patches to directly deliver PROTACs into tumors.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Jeselhy (pimitespib) / Otsuka
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  BrUOG 387: TAS-116 Plus Palbociclib in Breast and Rb-null Cancer (clinicaltrials.gov) -  Jun 28, 2023   
    P1,  N=27, Not yet recruiting, 
    The safety of denosumab did not differ among participants with and without CKD. Trial completion date: Apr 2025 --> Aug 2025 | Initiation date: May 2023 --> Aug 2023 | Trial primary completion date: Apr 2024 --> Aug 2024
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Inlyta (axitinib) / Pfizer, Bavencio (avelumab) / EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  APART: Avelumab, Palbociclib and Axitinib in Advanced RCC (clinicaltrials.gov) -  Jun 28, 2023   
    P2,  N=25, Not yet recruiting, 
    Trial completion date: Apr 2025 --> Aug 2025 | Initiation date: May 2023 --> Aug 2023 | Trial primary completion date: Apr 2024 --> Aug 2024 Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    New trial:  TezepelumabPRO: Tezepelumab PRO Study (clinicaltrials.gov) -  Jun 28, 2023   
    P=N/A,  N=90, Not yet recruiting, 
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Enrollment closed, Trial completion date, Trial primary completion date:  A Phase 4, Open-label Study of KRYSTEXXA (clinicaltrials.gov) -  Jun 28, 2023   
    P4,  N=40, Active, not recruiting, 
    Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2026 Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Nov 2023
  • ||||||||||  Reimbursement, US reimbursement, Journal:  Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs. (Pubmed Central) -  Jun 27, 2023   
    Descriptive analyses documented spending trends for patients receiving common outpatient-administered biologics used in cancer treatments (bevacizumab, filgrastim, pegfilgrastim, rituximab, and trastuzumab) at 340B (treated) and non-340B (control) hospitals...In this cohort study, new 340B participation was associated with statistically significant higher oncological drug episode spending compared with nonparticipants after changes in 340B inclusion rules in 2010. These findings raise questions about unintended consequences of the 340B program on drug spending from the commercially insured population.
  • ||||||||||  SB202190 / Amgen, PD98059 / Wayne State University, SP600125 / BMS
    Preclinical, Journal, IO biomarker:  Propofol Induces the Expression of Nrf2 and HO-1 in Echinococcus granulosus via the JNK and p38 Pathway In Vitro. (Pubmed Central) -  Jun 27, 2023   
    These results suggest that propofol induces an upregulated expression of HO-1 and Nrf2 by activation of the JNK and p38 MAPK signaling pathways. This study highlights the cross role of metabolic regulation of ROS signaling and targeting signalling pathways that may provide a promising strategy for the treatment of E. granulosus disease.
  • ||||||||||  Neulasta (pegfilgrastim) / Roche
    Trial completion, Phase classification, Trial completion date, Trial primary completion date:  AML-12: Risk-adapted Therapy for Primary Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 27, 2023   
    P2,  N=1034, Completed, 
    Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023 Recruiting --> Completed | Phase classification: PN/A --> P2 | Trial completion date: Oct 2021 --> Nov 2022 | Trial primary completion date: Oct 2021 --> Jul 2022
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  NeupoNET: G-CSF in the Treatment of Toxic Epidermal Necrolysis (clinicaltrials.gov) -  Jun 27, 2023   
    P4,  N=10, Completed, 
    Recruiting --> Completed | Phase classification: PN/A --> P2 | Trial completion date: Oct 2021 --> Nov 2022 | Trial primary completion date: Oct 2021 --> Jul 2022 Recruiting --> Completed | Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Jul 2022 --> Mar 2023
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies. (Pubmed Central) -  Jun 26, 2023   
    Blinatumomab, a CD19-CD3 BiTE is now a widely used therapy for relapsed B-cell malignancies, and similar BiTE therapeutics have shown promise for treating various other forms of cancer...By testing several novel CD3-targeting scFv elements for activity in EGFRvIII-targeted BiTEs, we were able to identify highly active BiTE molecules with desirable functional activity for downstream development. In summary, BiTE-J presents a low cost, high-throughput method for the rapid assessment of novel BiTE molecules without the need for purification and quantification.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Journal:  Identification of Potent hDHODH Inhibitors for Lung Cancer via Virtual Screening of a Rationally Designed Small Combinatorial Library. (Pubmed Central) -  Jun 26, 2023   
    Among the tested compounds, compound 5c possessed a stronger cytotoxicity (TC of 11 ?M) compared to the standard FDA-approved drug (Regorafenib, TC of 13 ?M) on the A549 cell line...DFT, molecular docking, molecular dynamic simulations, and free energy calculations were also carried out to understand the inhibitory mechanisms of the synthesized scaffolds. These in silico studies identified key mechanisms and structural features that will be crucial for future studies.
  • ||||||||||  Journal:  Biologics for the treatment of severe asthma: Current status report 2023 (Pubmed Central) -  Jun 26, 2023   
    Existing studies have shown that all the approved biologic agents targeting cells, receptors, and mediators involved in type 2 inflammation in the bronchial wall in severe asthma significantly reduce asthma exacerbations, reduce the need for oral corticosteroids, and improve asthma control, quality of life, and pulmonary functions. Characterizing the asthma endotype and phenotype in patients with severe asthma and determining which treatment would be more appropriate for a particular patient is an essential step in personalized treatment.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Bones of contention: Predicting and preventing fractures in patients receiving peritoneal dialysis. (Pubmed Central) -  Jun 26, 2023   
    Denosumab is more commonly used and has some evidence for improvement in BMD but carries with it a high risk of hypocalcaemia requiring rigorous prophylaxis. More research is needed to explore practical methods to identify those at risk of fracture and determine the efficacy of antiresorptive and anabolic therapies to decrease this risk.
  • ||||||||||  Tavneos (avacopan) / Kissei, Amgen, Otsuka, Soliris (eculizumab) / AstraZeneca
    Journal:  C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection. (Pubmed Central) -  Jun 26, 2023   
    Lower serum C5a concentrations or a C5 polymorphism that decreases leukocyte C5 expression correlated independently with poor patient outcomes. Thus, local, phagocyte-derived C5 production licenses phagocyte antimicrobial function and confers innate protection during systemic fungal infection.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  An improved total en bloc spondylectomy for L5 vertebral giant cell tumor through a single-stage posterior approach. (Pubmed Central) -  Jun 26, 2023   
    Single-stage posterior TES for L5 GCT was previously considered impossible. In this study, we presented our experience with the use of an improved surgical technique for L5 TES through the single-stage posterior approach, which has proved to be superior to the conventional procedures in terms of blood loss control and complication and recurrence rates.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal:  Treatment outcomes and time to healing of medication-related osteonecrosis of the jaw based on image findings. (Pubmed Central) -  Jun 26, 2023   
    The image findings on the internal texture of the lesions at the initial examination and chemotherapy were associated with the treatment outcomes of nonoperative management of MRONJ. The image findings of "Sequestrum formation" were associated with lesions taking a short time to heal and better outcomes, whereas "Sclerosis" and "Normal" were associated with lesions with longer healing times.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  Sotorasib (Lumakras) for NSCLC. (Pubmed Central) -  Jun 24, 2023   
    No abstract available No abstract available
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Trial suspension:  EREMISS: Phase II Study of Regorafenib as Maintenance Therapy (clinicaltrials.gov) -  Jun 23, 2023   
    P2,  N=126, Suspended, 
    In general, clinicians should consider potential thrombotic risks, address underlying risk factors, and ensure ongoing monitoring and follow-up when treating ITP patients with TAs. Recruiting --> Suspended